()

(NEW YORK)With research and development pipelines lagging and patent expirations on many key drugs looming, large pharmaceutical and biotech companies are increasingly looking to biotechnolo...READ MORE

(CHICAGO)Celgene Corp. said late Sunday that a mid-stage study showed that 29 percent of patients with a certain type of blood cancer responded to its drug Revlimid. The data was presented ...READ MORE

(NEW YORK)With cancer drugs making up the bulk of sales for many biotech companies, Wall Street is gearing up for one of the year's most anticipated medical conferences, the American Soc...READ MORE

The Japanese Takeda Pharmaceutical Co. agreed to buy Millennium Pharmaceuticals, Inc. a biotechnology company, for $8.8 billion on a move to remain competitive in the global market...READ MORE